EUVIMEDEUVIMED entdecken
Open Access

Comparison of Proteomic Measurements Across Platforms in the Atherosclerosis Risk in Communities (ARIC) Study

Mary R Rooney iD, Jingsha Chen, Christie M Ballantyne iD, Ron C Hoogeveen, Olive Tang, Morgan E Grams, Adrienne Tin iD, Chiadi E Ndumele, Faiez Zannad iD, David J Couper iD, Weihong Tang, Elizabeth Selvin iD und 1 weitere

Clinical Chemistry · 04.01.2023 · 69 (1) · 68-79

DOI: 10.1093/clinchem/hvac186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, online erschienen am 12.12.2022. Verfasst von Mary R Rooney und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Welch Center for Prevention, Epidemiology, & Clinical Research, Johns Hopkins Bloomberg School of Public Health, Balti…. Hauptthemen laut MEDLINE: Proteomics, Atherosclerosis. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIDDK NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The plasma proteome can be quantified using different types of highly multiplexed technologies, including aptamer-based and proximity-extension immunoassay methods. There has been limited characterization of how these protein measurements correlate across platforms and with absolute measures from targeted immunoassays.

Methods

We assessed the comparability of (a) highly multiplexed aptamer-based (SomaScan v4; Somalogic) and proximity-extension immunoassay (OLINK Proseek® v5003; Olink) methods in 427 Atherosclerosis Risk in Communities (ARIC) Study participants (Visit 5, 2011–2013), and (b) 18 of the SomaScan protein measurements against targeted immunoassays in 110 participants (55 cardiovascular disease cases, 55 controls). We calculated Spearman correlations (r) between the different measurements and compared associations with case-control status.

Results

There were 417 protein comparisons (366 unique proteins) between the SomaScan and Olink platforms. The average correlation was r = 0.46 (range: −0.21 to 0.97; 79 [19%] with r ≥ 0.8). For the comparison of SomaScan and targeted immunoassays, 6 of 18 assays (growth differentiation factor 15 [GDF15], interleukin-1 receptor-like 1 [ST2], interstitial collagenase [MMP1], adiponectin, leptin, and resistin) had good correlations (r ≥ 0.8), 2 had modest correlations (0.5 ≤ r < 0.8; osteopontin and interleukin-6 [IL6]), and 10 were poorly correlated (r < 0.5; metalloproteinase inhibitor 1 [TIMP1], stromelysin-1 [MMP3], matrilysin [MMP7], C-C motif chemokine 2 [MCP1], interleukin-10 [IL10], vascular cell adhesion protein 1 [VCAM1], intercellular adhesion molecule 1 [ICAM1], interleukin-18 [IL18], tumor necrosis factor [TNFα], and visfatin) overall. Correlations for SomaScan and targeted immunoassays were similar according to case status.

Conclusions

There is variation in the quantitative measurements for many proteins across aptamer-based and proximity-extension immunoassays (approximately 1/2 showing good or modest correlation and approximately 1/2 poor correlation) and also for correlations of these highly multiplexed technologies with targeted immunoassays. Design and interpretation of protein quantification studies should be informed by the variation across measurement techniques for each protein.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsAtherosclerosisHumansInterleukin-6ImmunoassayAdiponectin

Substanzen

Interleukin-6Adiponectin

Autor:innen und Institutionen

  • Department of Epidemiology and Welch Center for Prevention, Epidemiology, & Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MA, USA.
  • Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Department of Medicine, Johns Hopkins University, Baltimore, MA, USA.
  • Memory Impairment and Neurodegenerative Dementia (MIND) Center and Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
  • Université de Lorraine, Inserm CIC-P 1433 & U1116, CHRU Nancy, France.
  • Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, USA.

ORCID-Profile: Mary R Rooney, Christie M Ballantyne, Adrienne Tin, Faiez Zannad, David J Couper, Elizabeth Selvin

Förderung

  • NIGMS NIH HHS
  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NHLBI
  • NIH
  • Department of Health and Human Services
  • NIDDK

Zitieren

APA

Rooney, M. R., Chen, J., Ballantyne, C. M., Hoogeveen, R. C., Tang, O., Grams, M. E., Tin, A., Ndumele, C. E., Zannad, F., Couper, D. J., Tang, W., Selvin, E., & Coresh, J. (2023). Comparison of Proteomic Measurements Across Platforms in the Atherosclerosis Risk in Communities (ARIC) Study. Clinical Chemistry, 69(1), 68-79. https://doi.org/10.1093/clinchem/hvac186

Vancouver

Rooney MR, Chen J, Ballantyne CM, Hoogeveen RC, Tang O, Grams ME, et al. Comparison of Proteomic Measurements Across Platforms in the Atherosclerosis Risk in Communities (ARIC) Study. Clinical Chemistry. 2023;69(1):68-79. doi:10.1093/clinchem/hvac186

BibTeX
@article{Rooney2023,
  author = {Rooney, Mary R and Chen, Jingsha and Ballantyne, Christie M and Hoogeveen, Ron C and Tang, Olive and Grams, Morgan E and Tin, Adrienne and Ndumele, Chiadi E and Zannad, Faiez and Couper, David J and Tang, Weihong and Selvin, Elizabeth and Coresh, Josef},
  title = {Comparison of Proteomic Measurements Across Platforms in the Atherosclerosis Risk in Communities (ARIC) Study},
  journal = {Clinical Chemistry},
  year = {2023},
  volume = {69},
  number = {1},
  pages = {68--79},
  doi = {10.1093/clinchem/hvac186}
}
Kostenlos starten →